Atezolizumab plus Bevacizumab plus Tiragolumab
Sponsors
Roche
Conditions
Cancer
Phase 3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152/SKYSCRAPER-14)
Active, not recruitingPACTR202402574273311
Start: 2024-04-30Target: 650Updated: 2026-09-14
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
Active, not recruitingPACTR202405856204528
Start: 2024-05-13Target: 650Updated: 2026-09-14